Industry
Biotechnology
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients. The company was incorporated in 2019 and is based in Providence, Rhode Island.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 23, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Insights
June 10, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
May 30, 2024 | 11:46 am
Portfolio Pulse from Benzinga Newsdesk
May 16, 2024 | 12:02 pm
Portfolio Pulse from Benzinga Insights
May 14, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Insights
May 02, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Newsdesk
April 24, 2024 | 8:52 pm
Portfolio Pulse from Avi Kapoor
March 07, 2024 | 6:35 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.